Can the test be used on cats and other animals?

At this time, we only offer commercial services to canine lymphoma patients. However, we are conducting research into feline lymphoma so if you would like to submit a sample please sign up here if you are interested in feline services.

Other Questions

Back to Help Center

What is a drug sensitivity test?

A drug sensitivity test is a lab test that measures how easily cells are killed by a drug.When you order a Personalized Prediction Profile, ImpriMed uses a proprietary high-throughput ex vivo drug sensitivity testing platform to analyze your patient’s live cells. For our canine leukemia and lymphoma service, we expose the cells to 13 different drugs commonly used to treat these diseases: L-Asparaginase, Mitoxantrone, Vincristine, Vinblastine, Doxorubicin, Rabacfosadine (Tanovea®), Chlorambucil, Mechlorethamine, Lomustine, Prednisolone (activated Prednisone), Mafosfamide (activated Cyclophosphamide), Melphalan, and Dexamethasone.-

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

Can we select non-MDR substrate drugs for known or suspected MDR dogs?

Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.

What is included in the ImpriMed Immunoprofile service?

The ImpriMed Immunoprofile service includes both our Flow Cytometry and PARR reports. These comprehensive results can be used to detect the presence of lymphoma or leukemia and determine the disease subtype.

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.